Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA CAR-T for Relapsed/Refractory Multiple Myeloma
NCT04271644Phase 2Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Apr 2019
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of BCMA CAR-T cells in multiple myeloma (MM), plasma cell neoplasm, sponsored by Chongqing Precision Biotech. Started Apr 2019; status: recruiting.
02
Drugs
BCMA CAR-T cells
03
Conditions
multiple myeloma (MM)plasma cell neoplasm
Beyond the preview
Go deeper on NCT04271644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04271644.